A VIP ANTAGONIST DISTINGUISHES VIP RECEPTORS ON SPINAL-CORD CELLS AND LYMPHOCYTES

被引:63
作者
GOZES, Y
BRENNEMAN, DE
FRIDKIN, M
ASOFSKY, R
GOZES, I
机构
[1] NICHHD,DEV NEUROBIOL LAB,NEUROCHEM UNIT,BLDG 36,ROOM 2A21,BETHESDA,MD 20892
[2] NIAID,IMMUNOL LAB,BETHESDA,MD 20892
[3] ISRAEL INST BIOL RES,IL-70450 NESS ZIONA,ISRAEL
[4] WEIZMANN INST SCI,DEPT ORGAN CHEM,IL-76100 REHOVOT,ISRAEL
[5] TEL AVIV UNIV,SACKLER SCH MED,DEPT CHEM PATHOL,TEL AVIV,ISRAEL
关键词
VASOACTIVE INTESTINAL PEPTIDE; SPINAL CORD CELL CULTURE; LYMPHOCYTE; VASOACTIVE INTESTINAL RECEPTOR; VASOACTIVE INTESTINAL PEPTIDE RECEPTOR ANTAGONIST;
D O I
10.1016/0006-8993(91)90528-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Vasoactive intestinal peptide (VIP) is a neuropeptide which also interacts with cells of the immune system. The paucity of specific VIP receptor antagonists has hampered studies of possible receptor heterogeneity and of VIP function. To aid in achieving these goals, a new VIP antagonist, a hybrid between neurotensin and VIP, has been synthesized. This peptide interacted with VIP receptors on spinal cord cells with an affinity 10-fold greater than VIP itself. In contrast, 1000-fold higher concentrations of the antagonist were required to displace labeled VIP from its receptor on lymphoid cells as compared to VIP itself, suggesting VIP receptor heterogeneity between immune and spinal cord cells.
引用
收藏
页码:319 / 321
页数:3
相关论文
共 15 条
[1]   VASOACTIVE-INTESTINAL-PEPTIDE AND ELECTRICAL-ACTIVITY INFLUENCE NEURONAL SURVIVAL [J].
BRENNEMAN, DE ;
EIDEN, LE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (04) :1159-1162
[2]  
FINCH RJ, 1989, J IMMUNOL, V142, P1977
[3]  
GOZES I, 1989, Society for Neuroscience Abstracts, V15, P216
[4]   VASOACTIVE INTESTINAL PEPTIDE POTENTIATES SEXUAL-BEHAVIOR - INHIBITION BY NOVEL ANTAGONIST [J].
GOZES, I ;
MELTZER, E ;
RUBINROUT, S ;
BRENNEMAN, DE ;
FRIDKIN, M .
ENDOCRINOLOGY, 1989, 125 (06) :2945-2949
[5]  
GOZES I, IN PRESS HYBRID ANTA
[6]  
GOZES I, 1989, MOL NEUROBIOL, V3, P1
[7]  
ODORISIO MS, 1985, J IMMUNOL, V134, P4078
[8]  
OTTAWAY CA, 1984, J IMMUNOL, V132, P417
[9]  
OTTAWAY CA, 1987, IMMUNOLOGY, V62, P291